PURPOSE: The 21-gene Recurrence Score (RS) assay is used to predict disease recurrence and benefit of chemotherapy in estrogen receptor-positive, lymph node-negative early-stage breast cancer (EBC). Our study is the first analysis of trends and differences in the use of the RS assay and its impact on recommending chemotherapy in a population-based data set. METHODS: Patients with EBC diagnosed from 2004 to 2012 and included in the National Cancer Data Base were analyzed. Multivariate logistic regression analysis was used to estimate the covariates associated with use of the test and its impact on chemotherapy decisions. RESULTS: The RS assay was ordered for 54.0% of the 143,032 identified patients. Of all the variables, RS assay had the strongest association with recommendation for chemotherapy, with an adjusted odds ratio (AOR) of 83 for high assay scores. When indicated, test use was significantly associated with younger age, white race, academic centers, private insurance, and pT2/pN0(i+) grade 2 to 3 disease. Black patients (AOR, 1.31; 95% CI, 1.20 to 1.43) and those treated in community facilities (AOR, 1.49; 95% CI, 1.35 to 1.63) were more likely to be tested outside the National Comprehensive Cancer Network guidelines. Black patients (AOR, 1.51; 95% CI, 1.31 to 1.69) and those with high tumor grade (AOR, 30.76; 95% CI, 26.48 to 35.73) had significantly higher assay scores. Younger black patients (AOR, 1.33; 95% CI, 1.16 to 1.54) were more likely to receive chemotherapy despite low assay scores. CONCLUSION: The RS assay significantly influences clinicians' recommendations for chemotherapy in patients with EBC. Black patients tended to have higher assay scores, which may reflect use patterns or less favorable tumor biology for estrogen receptor-positive disease. There are significant differences in use and clinical implications of the test on the basis of race, insurance, and type of facility.
PURPOSE: The 21-gene Recurrence Score (RS) assay is used to predict disease recurrence and benefit of chemotherapy in estrogen receptor-positive, lymph node-negative early-stage breast cancer (EBC). Our study is the first analysis of trends and differences in the use of the RS assay and its impact on recommending chemotherapy in a population-based data set. METHODS:Patients with EBC diagnosed from 2004 to 2012 and included in the National Cancer Data Base were analyzed. Multivariate logistic regression analysis was used to estimate the covariates associated with use of the test and its impact on chemotherapy decisions. RESULTS: The RS assay was ordered for 54.0% of the 143,032 identified patients. Of all the variables, RS assay had the strongest association with recommendation for chemotherapy, with an adjusted odds ratio (AOR) of 83 for high assay scores. When indicated, test use was significantly associated with younger age, white race, academic centers, private insurance, and pT2/pN0(i+) grade 2 to 3 disease. Black patients (AOR, 1.31; 95% CI, 1.20 to 1.43) and those treated in community facilities (AOR, 1.49; 95% CI, 1.35 to 1.63) were more likely to be tested outside the National Comprehensive Cancer Network guidelines. Black patients (AOR, 1.51; 95% CI, 1.31 to 1.69) and those with high tumor grade (AOR, 30.76; 95% CI, 26.48 to 35.73) had significantly higher assay scores. Younger black patients (AOR, 1.33; 95% CI, 1.16 to 1.54) were more likely to receive chemotherapy despite low assay scores. CONCLUSION: The RS assay significantly influences clinicians' recommendations for chemotherapy in patients with EBC. Black patients tended to have higher assay scores, which may reflect use patterns or less favorable tumor biology for estrogen receptor-positive disease. There are significant differences in use and clinical implications of the test on the basis of race, insurance, and type of facility.
Authors: Juhi Asad; Allyson F Jacobson; Alison Estabrook; Sharon Rosenbaum Smith; Susan K Boolbol; Sheldon M Feldman; Michael P Osborne; Kwadwo Boachie-Adjei; Wendy Twardzik; Paul I Tartter Journal: Am J Surg Date: 2008-10 Impact factor: 2.565
Authors: Gong Tang; Steven Shak; Soonmyung Paik; Stewart J Anderson; Joseph P Costantino; Charles E Geyer; Eleftherios P Mamounas; D Lawrence Wickerham; Norman Wolmark Journal: Breast Cancer Res Treat Date: 2011-01-11 Impact factor: 4.872
Authors: Foluso O Ademuyiwa; Austin Miller; Tracey O'Connor; Stephen B Edge; Mangesh A Thorat; George W Sledge; Ellis Levine; Sunil Badve Journal: Breast Cancer Res Treat Date: 2011-01-01 Impact factor: 4.872
Authors: Richard H de Boer; Caroline Baker; David Speakman; Calvin Y Chao; Carl Yoshizawa; G Bruce Mann Journal: Med J Aust Date: 2013-08-05 Impact factor: 7.738
Authors: Megan C Roberts; Morris Weinberger; Stacie B Dusetzina; Michaela A Dinan; Katherine E Reeder-Hayes; Melissa A Troester; Lisa A Carey; Stephanie B Wheeler Journal: Breast Cancer Res Treat Date: 2015-07-28 Impact factor: 4.872
Authors: Leonard R Henry; Alexander Stojadinovic; Sandra M Swain; Sheila Prindiville; Rose Cordes; Peter W Soballe Journal: J Surg Oncol Date: 2009-05-01 Impact factor: 3.454
Authors: Shelly S Lo; Patricia B Mumby; John Norton; Karen Rychlik; Jeffrey Smerage; Joseph Kash; Helen K Chew; Ellen R Gaynor; Daniel F Hayes; Andrew Epstein; Kathy S Albain Journal: J Clin Oncol Date: 2010-01-11 Impact factor: 44.544
Authors: Carlos H Barcenas; Akshara Raghavendra; Arup K Sinha; Masood Pasha Syed; Limin Hsu; Modesto G Patangan; Mariana Chavez-MacGregor; Yu Shen; Gabriel H Hortobagyi; Vicente Valero; Sharon H Giordano; Naoto T Ueno; Debu Tripathy Journal: Cancer Date: 2017-02-15 Impact factor: 6.860
Authors: Tracy A Lieu; G Thomas Ray; Stephanie R Prausnitz; Laurel A Habel; Stacey Alexeeff; Yan Li; Scott D Ramsey; Charles E Phelps; Neetu Chawla; Suzanne C O'Neill; Jeanne S Mandelblatt Journal: Breast Cancer Res Treat Date: 2017-02-21 Impact factor: 4.872
Authors: Melissa A Troester; Xuezheng Sun; Emma H Allott; Joseph Geradts; Stephanie M Cohen; Chiu-Kit Tse; Erin L Kirk; Leigh B Thorne; Michelle Mathews; Yan Li; Zhiyuan Hu; Whitney R Robinson; Katherine A Hoadley; Olufunmilayo I Olopade; Katherine E Reeder-Hayes; H Shelton Earp; Andrew F Olshan; Lisa A Carey; Charles M Perou Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: Yunan Han; Zhi-Feng Miao; Min Lian; Lindsay L Peterson; Graham A Colditz; Ying Liu Journal: Breast Cancer Res Treat Date: 2020-09-14 Impact factor: 4.872